This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
FDA Conducting Safety Review of Certain Prostate Cancer Drugs
Studies Link GnRH Agonists to Increased Risk for Diabetes, Cardiovascular Disease
By News Staff
The FDA said in a May 3 news release that its review is ongoing, and the agency has not reached any conclusions about whether the products increase the risk of developing diabetes or cardiovascular disease. However, according to a May 3 safety communication from the agency, data from six studies that compared outcomes in patients undergoing ADT with those in patients not undergoing the treatment indicate a small increased risk for these conditions.
The FDA offered the following advice for physicians and patients:
- physicians should carefully weigh the benefits and risks of prescribing GnRH agonists when determining treatment;
- patients receiving GnRH agonists should be monitored for development of diabetes and cardiovascular disease;
- physicians should manage patients' cardiovascular risk factors, such as smoking and increases in blood pressure, cholesterol, blood sugar, and weight, according to current clinical practice; and
- patients should not stop their treatment with GnRH agonists unless told to do so by their physicians.
GnRH agonists also are used in children to treat central precocious puberty, as well as in women for the management of endometriosis, preoperative improvement of anemia caused by uterine fibroids and palliative treatment of advanced breast cancer. However, the FDA said there are no known comparable epidemiologic studies evaluating the risk of diabetes and cardiovascular disease in children or women.
FDA Safety Alert: "GnRH Agonists: Safety Review of Drug Class Used to Treat Prostate Cancer"
(May 3, 2010)